Axon Enterprise - AXON Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axon Enterprise in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXON shares.
View AXON analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 12-month price targets for Axon Enterprise's shares. Their AXON share price forecasts range from $120.00 to $232.00. On average, they anticipate the company's share price to reach $164.22 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price.
View analysts price targets for AXON or view top-rated stocks among Wall Street analysts.

Axon Enterprise's stock was trading at $157.00 at the beginning of 2022. Since then, AXON stock has decreased by 21.5% and is now trading at $123.27.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our AXON earnings forecast.

Axon Enterprise, Inc. (NASDAQ:AXON) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.62. The biotechnology company earned $285.61 million during the quarter, compared to analysts' expectations of $258.96 million. Axon Enterprise had a net margin of 14.20% and a trailing twelve-month return on equity of 12.57%. Axon Enterprise's revenue for the quarter was up 30.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.72) earnings per share.

Axon Enterprise issued an update on its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.07 billion-$1.12 billion, compared to the consensus revenue estimate of $1.27 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axon Enterprise investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Axon Enterprise trades on the NASDAQ under the ticker symbol "AXON."

Axon Enterprise's stock is owned by many different retail and institutional investors. Top institutional investors include Moody National Bank Trust Division (0.03%). Insiders that own company stock include Adriane M Brown, Caitlin Elizabeth Kalinowski, Hadi Partovi, Jawad A Ahsan, Jeffrey C Kunins, Joshua Isner, Julie A Cullivan, Luke Larson, Mark W Kroll, Matthew R Mcbrady, Matthew R Mcbrady and Patrick W Smith.
View institutional ownership trends.

Shares of AXON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXON stock can currently be purchased for approximately $123.27.

Axon Enterprise (NASDAQ:AXON) has a market capitalization of $8.76 billion and generates $863.38 million in revenue each year. The biotechnology company earns $-60,020,000.00 in net income (profit) each year or $1.95 on an earnings per share basis.

The company employs 2,992 workers across the globe.

Axon Enterprise's mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The official website for the company is www.axovant.com. The biotechnology company can be reached via phone at (480) 991-0797, via email at ir@axon.com, or via fax at 480-991-0791.